



UNEXPECTED COMPLEXITY OF TRACING PARTICIPANTS FOR AN OPEN LABEL EXTENSION (OLE) Trial

Brenda Gati Mirembe, MBChB, MSc Epi

MU-JHU RESEARCH COLLABORATION

MTN REGIONAL MEETING, CAPE TOWN,SA 19 September 2017

Presentation Outline

- Introduction
- Tracing process MU-JHU experience
- Results
- Challenges
- Conclusion
- Acknowledgement







Introduction

- OLE trials are conducted to;
 - Provide access to efficacious products
 - Understand better the factors of adherence, acceptability, safety etc. in context of known efficacy
- MTNo25/HOPE, IPMo32/DREAM are examples of such trials
- Time between end of efficacy trial and start of OLE may have impact on accrual



MU-JHU Tracing Experience for HOPE

- Mar 2016 realization that HOPE will take place
- Jun 2016 Durban meeting
- Jul through Aug 5 participant engagement workshops
 - Inform them about HOPE
 - Difference between HOPE and ASPIRE
 - Introduce concepts of CHOICE, ADHERENCE and OPEN REPORTING
 - Obtain current contact information
- Jul thru Aug 10 community engagement workshops
 - Disseminate ASPIRE results
 - Inform them about HOPE study



Accrual/Tracing process (1)

- Recruitment Tools
 - Contact Log
 - Recruitment Log
 - Pre-screening Checklist
 - ASPIRE Locators
 - Attendance lists with participants contacts form
 Pre-HOPE Engagement workshops
- Site Activation occurred 05 Nov 16(16months)





Accrual/Tracing process(2)

- 242 potentially eligible former ASPIRE participants assigned to our site
- Community educators randomly distributed ASPIRE PTID lists amongst themselves (4)
- Each was tasked to contact at least 4
 participants on weekly basis--accrual targets
 - Weekend calls
- Screening visits scheduled based on clinic workload



Accrual/Tracing process (3)

- Several tracing approaches used;
 - Phone calls



- Home visiting using ASPIRE locator maps if phone contacts unsuccessful
- Use of former ASPIRE participants
- Use of HOPE study staff
- Community contact persons












Results(1)

- Successfully contacted 227 of 242 (94%)
 - Successful phone contacts 197
 - Home visits 9
 - Through fellow participants –12
 - Through HOPE staff 7
 - Opportunistic accrual 1 (had come for FP)
 - Community Contact person 1
- Totally failed to contact 14
- Did not give PTC 1
- All successful contacts had prescreening checklist administered

Results (2)

Successfully contacted 227 of 242 (94%)




Pre screening failure reasons

Total – 38 (never came for screening)



- Not Interested
- Pregnant
- Intends to Conceive
- Not Willing to use FP
- Relocated
- HIV Infected



Screening Enrol Status(15 Sep 17)

- Total screened--189
- Enrolled (72%)
 - Main study -171
 - Decliner 4
- Screen out reasons
 - Out of window (7)
 - HIV infected (2)
 - Refused by mother (1)
 - IoR discretion (1)







Challenges

- Relocations (Oman, Dubai)
- Many pregnant, breastfeeding..
- Change in phone contact, locator information
- Network/connectvity issues
- Convincing women to wait for their turn
- Participants not keeping appointments
- May 2017 saga—all unregistered phones to be switched off....







In conclusion

- Accrual for OLE requires multifaceted approach given that people are not static
- Starting early to sensitize potential participants for possible OLE is crucial
- Good coordination, TEAM work are paramount
- Never give up go extra mile!





Opportunistic engagement



Acknowledgements

- MU-JHU Community team and MTNo25 staff
- MU-JHU Site leadership
- The Microbicide Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health



